The solubility-driven optimization of a series of 1,7-napthyridine phosphodiesterase-4 inhibitors is described. Directed structural changes resulted in increased aqueous solubility, enabling superior pharmacokinetic properties with retention of PDE4 inhibition. A range of potent and orally bioavailable compounds with good in vivo efficacy in animal models of inflammation and reduced emetic potential compared to previously described drugs were synthesized. Compound 2d was taken forward as a clinical candidate for the treatment of COPD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/jm300459a | DOI Listing |
Publication Analysis
Top Keywords
solubility-driven optimization
8
phosphodiesterase-4 inhibitors
8
clinical candidate
8
optimization phosphodiesterase-4
4
inhibitors leading
4
leading clinical
4
candidate solubility-driven
4
optimization series
4
series 17-napthyridine
4
17-napthyridine phosphodiesterase-4
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!